Fishawack, a leading independent healthcare communications specialist, announced the acquisition of Philadelphia-based healthcare communications agency Dudnyk.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.
EVERSANA, the leading independent provider of global services to the life science industry, introduced a new suite of global market access solutions from Health Strategies Insights to help biopharmaceutical manufacturers understand the latest global trends in access, payment, distribution and administration.
The Inception Company Partners with WEGO Health to Launch a Virtual Patient Collaboration Platform via Pando
The Inception Company, a technology-driven production company, and WEGO Health, the premiere network of patient opinion leaders and health influencers, announced the launch of “Patient Co-Lab.”
March is National Women’s Month, and BioSpace recognized these 10 women as being especially influential in the biopharma industry.
Healthline Invigorates its Board by Adding Proven Brand Builder with Deep Product, Marketing and Media Expertise
Healthline Media Inc. announced the addition of a new member to the company’s board of directors with a track record of creating blockbuster brands: Kira Wampler.
Alcon, the eye care division of Novartis, acquired fluid-based intraocular lens maker PowerVision Inc. for $285 million.
The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.
Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.
A California jury awarded $29 million to a woman who said abestos in Johnson & Johnson’s talcum-powder-based products caused her cancer.